ArticleFrontiers in endocrinology2025
Association of Placental Growth Factor with the risk of adverse pregnancy outcomes: a prospective cohort study in Chinese pregnant women.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quercetin protects HTR-8/SVneo human trophoblast cells against oxidative stress injury via activating EGFR/PI3K/AKT-NRF2/HO-1 signaling axis.Frontiers in pharmacology · 2026Article
- Utility of Placental Growth Factor for the Prediction of Miscarriage in the First Trimester of Pregnancy: A Case-Control Study.International journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adverse pregnancy outcomes, such as preterm birth, preeclampsia (PE), small for gestational age (SGA), pose significant risks to maternal and neonatal health and contribute to healthcare burdens. Placental Growth Factor (PIGF), a key pro-angiogenic biomarker involved in placental development, has been implicated in the pathophysiology of these complications. This study aimed to investigate the association between maternal serum PIGF levels and adverse pregnancy outcomes in a prospective cohort. Methods: We conducted a cohort study involving 5,870 women with singleton pregnancies enrolled at Nanjing Drum Tower Hospital from January 2017 to September 2020. Participants were followed from early pregnancy (≤14 gestational weeks) through delivery. Logistic regression models were used to evaluate the associations between serum PIGF levels (measured at 11-14 gestational weeks) and adverse pregnancy outcomes, reported as adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Dose-response relationships were assessed using restricted cubic spline analysis. Results: Serum PIGF concentrations in early pregnancy were inversely associated with PE (OR = 0.97, 95% CI:0.96 - 0.98), preterm PE (OR = 0.96, 0.94 - 0.98), SGA <10th percentile (OR = 0.99, 0.98 - 0.99) and SGA <3rd percentile (OR = 0.98, 0.97 - 0.99). Expressed as multiples of the median (MoM), PIGF showed stronger associations with these outcomes, including PE (OR = 0.32, 0.21 - 0.48), preterm PE (OR = 0.23, 0.09 - 0.56), SGA <10th percentile (OR = 0.67, 0.54 - 0.83) and SGA <3rd percentile (OR = 0.43, 0.29 - 0.64), compared with its absolute concentrations. Notably, PIGF demonstrated a consistent inverse association with PE across different modes of conception, including spontaneous pregnancies (OR = 0.97, 0.96 - 0.98) and those conceived via ovulation induction or Conclusion: This cohort study reinforces the inverse association between maternal PIGF levels and the risks of PE and SGA. The findings highlight the potential clinical utility of PIGF as a gestational age-specific biomarker in prenatal risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.